drugset / Trial / NCT03179930
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Phase 2
Active not recruiting
47 enrolled
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC · collabSyndax Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.
Timeline
- Start
- 2017-06-07
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entinostat | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |